Keywords: boeh, ingelheim, abbott, marketing, deal, boehringer, laboratories
Boeh Ingelheim & Abbott in US marketing deal
Article | 04 March 1999
Boehringer Ingelheim and Abbott Laboratories have entered into aneight-year deal by which the latter will distribute and copromote BI's Micardis ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
